Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

IND investigation versus BLA marketing review

In one sentence

An investigational application supports defined human use during research or access, while a marketing application asks for authorization to market a product for a specified use.

The intuition

Permission to investigate a product and permission to market it are different doors. Passing through the first can let researchers gather the evidence needed for the second. It does not mean the second door will open.

This is a memory aid rather than a universal straight line. Some investigations concern already marketed products, and treatment access outside a trial can also use an investigational application.

How it works

An Investigational New Drug (IND) application is the U.S. regulatory mechanism supporting specified investigational use of a drug or biologic. It includes relevant nonclinical information, manufacturing information and clinical protocols. The Food and Drug Administration (FDA) assesses whether the proposed use can proceed without unreasonable risk under the applicable framework.

An IND becoming effective or a use being allowed to proceed is not marketing approval. A clinical hold can prevent or interrupt an investigation. An IND number identifies the application; it does not certify benefit, establish enrollment or authorize every future product version and protocol.

A Biologics License Application (BLA) requests authorization to market a biological product. Its evidence package addresses safety, effectiveness, manufacturing quality and proposed labeling. Biological products include categories such as vaccines and certain cell or gene therapies. The applicable regulatory center and pathway depend on the actual product.

A New Drug Application (NDA) is a drug marketing application. It is another marketing door, rather than an earlier stage that every BLA must pass through. A BLA submission, FDA filing review and an approval decision are different milestones.

Both investigational and marketing pathways can concern product quality. “They looked at manufacturing” therefore cannot tell you which regulatory decision occurred. A new formulation or manufacturing change needs its applicable review; sharing an ingredient or platform name does not automatically carry forward another authorization.

Why it matters in cancer

A clinic or company may mention an IND when discussing an investigational treatment. Ask what product, protocol and sponsor it covers. An existing application may support a new protocol only through the applicable submission and review steps.

A single-patient IND is one mechanism for expanded access. It concerns a proposed treatment use, not a new marketing approval. Supplier agreement, clinical readiness and required reviews remain separate.

How the status is checked

The output is documentary, without a biological unit. Ask for the exact application type, sponsor, covered product/use, current decision and limitations. For a marketed product, inspect the current approval and label. An application number or a submitted dossier alone is insufficient.

An IND is not a public catalogue guaranteeing access. The clinical team and sponsor confirm the relevant protocol and any required permissions. Product availability and institutional ability to deliver it remain practical questions.

Common confusions

  • An IND allowed to proceed is not an approved BLA.
  • A BLA filed for review is not an approved BLA.
  • A new use of an approved drug may be off label, while a never-approved product requires an investigational route.
  • Application type does not identify the strength of every clinical claim; approval pathways explain another axis.

Try it

A fictional message says, “Our biologic has an active IND and we submitted the BLA, so it is FDA-approved.” What needs correction?

Answer: The described milestones are investigation and a marketing request. An actual approval decision and label are still needed before calling the product approved for a use. Neither milestone guarantees access for a particular person.

Investigator-initiated trials identifies sponsor duties. Manufacturing comparability asks how process changes affect earlier evidence.

Sources and scope

U.S. source check: October 9, 2026. The example is fictional. No individual application status or authorization is asserted. Expert and learner review pending.

Used in